Discovery platform for antiviral agents to SARS-CoV-2 and other high risk pathogens in a BSL-3+ laboratory

In collaboration with the Medical University Graz and the computational biology company Innophore, acib is offering a powerful drug discovery and repurposing platform. The platform consists of an advanced computational modeling technology and of a high-end BSL-3+ laboratory for in-vitro drug testing and access to patient material including virus isolates.

**BACKGROUND**

The current Covid-19 situation demonstrates the need for rapid access to new drugs. By combining advanced computational modeling and a series of in-vitro assays established in a high-end BSL-3+ laboratory, available drugs and chemical compounds can be rapidly tested for antiviral activity including high-risk pathogens. The use of different in-vitro models along with human organoids reduces the need for animal models and provides a solid pre-clinical data base for drug repurposing and rapid clinical application.

**TECHNOLOGY**

We can perform three phase in-vitro testing of antiviral drugs including evaluation of toxicity, evaluation of antiviral activity in different cell lines and antiviral activity in human organoids. The read-out is based on cytopathic effects, qPCR and plaque assays. In the high-end BSL-3+ laboratory we can establish and characterize viral cultures from patient samples and test the relevance of different sub-strains.

**OFFER**

We are offering pre-clinical R&D services and co-development of drugs against various types of high risk pathogens including SARS-CoV-2.

---

**EXPERTS**

Prof. Dr. Kurt Zatloukal  
Dr. Christian Gruber

**AVAILABLE FOR**

- Joint Research Project  
- Contract Research  
- COMET Funding call

**DEVELOPMENT STATUS**

Ready for external services

**KEYWORDS**

- Biological Safety Lab  
- Structural biology  
- Computational modeling  
- In-vitro drug testing  
- High-risk pathogens  
- SARS-CoV-2  
- Covid-19  
- Patient samples  
- Diagnostics

**CONTACT**

acib GmbH, Krenngasse 37, 8010 Graz  
☎ +43 316 873 9316  
✉ bd@acib.at  
🌐 www.acib.at